U.S. News Room
December 16, 2021
Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for the Treatment of Pediatric Patients with Iron Deficiency Anemia
Download
December 11, 2021
Valemetostat Pivotal Data Shows Promising Response Rates in Patients with Adult T-Cell Leukemia/Lymphoma
Download
December 09, 2021
ENHERTU® Additional Analyses Further Reinforce Groundbreaking Efficacy in Patients with HER2 Positive Metastatic Breast Cancer
Download
December 07, 2021
Datopotamab Deruxtecan Continues to Show Promising Durable Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer
Download
December 01, 2021
Daiichi Sankyo to Present New Breast Cancer Data Across DXd ADC Portfolio at 2021 SABCS
Download
November 30, 2021
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer
Download
November 18, 2021
Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AML
Download
November 18, 2021
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Download
October 25, 2021
Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer
Download
October 04, 2021
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
Download